Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo Controlled, Double-blind, Double-dummy, Three-way Crossover Trial to Investigate the Effect of Two Doses of BI 474121 on Ketamine Induced Cognitive Deficits in Healthy Male Subjects

Next Previous
Trial Profile

A Randomized, Placebo Controlled, Double-blind, Double-dummy, Three-way Crossover Trial to Investigate the Effect of Two Doses of BI 474121 on Ketamine Induced Cognitive Deficits in Healthy Male Subjects

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 474121 (Primary) ; Ketamine
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 28 Jul 2022 Status changed from not yet recruiting to withdrawn prior to enrolment on termination of project.
  • 27 Jul 2022 Planned End Date changed from 12 Jun 2023 to 20 Jun 2023.
  • 13 Jul 2022 Planned End Date changed from 1 Mar 2023 to 12 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top